People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Other Health Care, Other, Other Technology, Manufacturing, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Melinta Therapeutics, Inc. /New/ | — | Pharmaceuticals | Series D+ | $346.8M | $4.9B | 2017 |
| Calypso Medical Technologies Inc | — | Other Health Care | Series C | $69.5M | $171.5M | 2009 |
| ECPM Holdings, LLC | — | Other | Series B | $56.9M | $515.1M | 2014 |
| Evolus, Inc. | — | Pharmaceuticals | Series B | $40.5M | $1.4B | 2020 |
| Rapidpulse, Inc. | — | Other Technology | Series A | $25.6M | $124.1M | 2021 |
| STRATA Skin Sciences, Inc. | — | Manufacturing | Series B | $17.5M | $4.0M | 2018 |
| Perimetrics, Inc. | — | Biotechnology | Series A | $17.2M | $60.4M | 2024 |
| Bridge To Life Ltd | — | Other Health Care | Pre-Seed | $1.0M | $4.0M | 2024 |
David Gill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Gill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Uri Geiger | 2 | 6 |
| Robert Hayman | 2 | 2 |
| John Johnson | 1 | 25 |
| Garheng Kong | 1 | 16 |
| Scott Davis | 1 | 10 |
| David Kaufman | 1 | 7 |
| Jeanne Cunicelli | 1 | 7 |
| Ross Jaffe | 1 | 7 |
| Scott Huennekens | 1 | 7 |
| Alan Levy | 1 | 7 |
| Michael Sweeney | 1 | 7 |
| John Freund | 1 | 7 |
| Dov Goldstein | 1 | 6 |
| MARK GILREATH | 1 | 6 |
| Scott Carter | 1 | 6 |
| James Eadie | 1 | 6 |
| Richard Kent | 1 | 5 |
| Alan Frazier | 1 | 5 |
| RIK VANDEVENNE | 1 | 5 |
| Simone Blank | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.